Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit?

Matthew Gallitto, Kunal Sindhu, Isaac Wasserman, Brian De, Vishal Gupta, Brett A. Miles, Eric M. Genden, Marshall Posner, Krzysztof Misiukiewicz, Richard L. Bakst

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: With increasing adoption of transoral robotic surgery (TORS) for oropharyngeal cancer (OPC), more patients may receive trimodality therapy. We sought to investigate outcomes and toxicities in this cohort. Methods: A retrospective study of patients with OPC treated with trimodality therapy at a tertiary-care hospital, comparing those receiving bilateral vs unilateral neck radiation. Results: Four hundred thirty-six patients underwent TORS, 17% receiving adjuvant chemoradiation. Of the 46 patients completing adjuvant treatment in-house, contralateral neck was spared in 20%. There were no significant differences in survival, and patient-reported outcomes in salivary function, mood, and anxiety were superior in those patients receiving unilateral neck radiation and directly correlated with mean dose to local structures. Conclusions: Surgery for OPC offers the potential for reduction in radiation volumes by omitting the contralateral neck in those who may have required definitive chemoradiation. Even in patients receiving concurrent chemotherapy, unilateral neck radiation has a favorable toxicity profile without compromising survival.

Original languageEnglish
Pages (from-to)3009-3022
Number of pages14
JournalHead and Neck
Issue number9
StatePublished - Sep 2019


  • neck dissection
  • oropharyngeal cancer
  • radiation therapy
  • transoral robotic surgery (TORS)
  • trimodality therapy


Dive into the research topics of 'Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit?'. Together they form a unique fingerprint.

Cite this